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Rationale for this review
Ideally, all systemic lupus erythematosus (SLE) patients 
should be reviewed by a specialist. Early referral to a 
rheu matologist has been associated with faster treatment 
modification and better outcomes. However, primary care 
doctors are the first point of care for new SLE patients or those presenting 
with a new complication. Moreover, given the shortage of rheumatologists 
in South Africa (SA) and elsewhere in Africa, primary care clinicians and 
general physicians are often faced with sick SLE patients and are required 
to make rapid therapeutic decisions. This review summarises current 
evidence for the treatment of SLE and its complications. We prepared 
this review after a PubMed search using the words ‘systemic lupus 
erythematosus’ and ‘therapy’.
General principles of management
Education and support
At diagnosis, patients should be offered counselling and educational 
material, preferably by a rheumatology nurse. Lupus support groups 
are very beneficial. Patients should avoid sun exposure and use a daily 
sunscreen (sun protection factor (SPF) >50).
Antimalarial therapy
The antimalarial (AM) drugs chloroquine (CQ) and hydroxy chloro­
quine (HQ) have been used in the treat ment of SLE for >50 years, 
with CQ being much more readily available in SA than HQ. Recent 
studies demonstrate their anti­inflammatory, antithrombotic and 
antilipidaemic effects via multiple molecular pathways, resulting in 
better control of disease activity and fewer complications (Table 1).[1] 
Given the current evidence, all SLE patients should be prescribed 
an AM, and clinicians should encourage compliance. The common 
side­effects of AM drugs are gastrointestinal, but these are usually 
mild and transient. More worrisome are skin hyperpigmentation 
and maculopathy. The latter is uncommon, affecting 2.5% of patients 
treated with CQ for 10 years (and 0.1% of patients using HQ); the major 
risk factor seems to be the cumulative dose of an AM.[2] If diagnosed 
early, and the AM is discontinued, the maculopathy is reversible. 
Therefore, patients on AMs should undergo ophthalmological 
assessment including fundoscopy, visual field tests and optical 
coherence tomography at baseline and annually after 5 years of CQ use.
Corticosteroids – less is more
Corticosteroids (CS) offer excellent control of active disease, but 
are responsible for most of the irreversible organ damage in SLE 
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Table 1. Clinical effects of antimalarial therapy in systemic 
lupus erythematosus
SLE disease and survival ↓   Number and severity of lupus flares 
Particularly useful for joint, skin and 
renal involvement
↓  Damage scores
↑  Long­term survival 
SLE onset in lupus­like disease Delay time to fulfilment of SLE criteria
Thrombosis ↓   Antiphospholipid­induced 
thrombosis 
Lipid profile ↓  Dyslipidaemia (↓ TG, ↓ VLDL, ↓ TC) 
↓  Atherosclerosis, ↓ CV events
Glycaemic status ↓   Insulin resistance and ↓ risk of 
diabetes, improves glucose control 
in diabetics
Infections Antimicrobial: ↓ infections 
↓  Bone mass loss
Pregnancy ↓   Risk of congenital heart block in 
infants
↓  Number and severity of lupus flares 
TG = triglycerides; VLDL = very low­density lipoproteins; TC = total cholesterol; 
CV = cardiovascular.
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patients 15 years after diagnosis.[3] The damage is propor tional to 
both the cumulative dose of CS and the average daily dose, and even 
low doses (<7.5  mg daily) are associated with a risk of cataracts, 
cardiovascular (CV) disease and osteoporosis.[4] The best practice 
is to prescribe CS only to patients with severe organ involvement at 
the lowest effective dose for the shortest duration of time possible. 
A recent study demonstrated that moderate doses (≤30 mg/day) of 
CS for severe non­renal SLE were as effective and associated with 
fewer adverse effects than high doses.[5] Another study demonstrated 
that after pulse methylprednisolone, oral CS may be omitted from 
an induction immunosuppressive regimen for nephritis.[6] An 
understanding of currently available immunosuppressant drugs such 
as methotrexate (MTX), azathioprine (AZA), cyclophosphamide 
(CYC) and mycophenylate mofetil (MMF) is vital in a steroid­sparing 
approach (Table 2).
Monitoring SLE patients
For patients with inactive disease, 4­monthly visits should 
include a clinical examination, blood pressure measurement, 
urine dipstick test, full blood count, and liver transaminase for 
those using potentially hepatotoxic medication. Other serum 
markers of active disease such as complement (C3 and C4), 
double­stranded DNA (dsDNA), and C­reactive protein may 
be useful for follow­up, but do not accurately predict flares. 
An annual lipogram, creatinine measurement, and HIV test 
are recommended. Screening for antiphospholipid antibodies at 
diagnosis is useful. As therapy of acute SLE improves, patients live 
longer. Therefore, comorbidities of the disease or complications 
of therapy have emerged as important causes of morbidity and 
mortality. Preventive and therapeutic strategies are summarised 
in Table 3.
Infections
The combination of inherent immune dysfunction and immuno­
suppressant therapy, in particular CS, puts SLE patients at high 
risk of community­acquired and opportunistic infections.[7] These 
infections contribute significantly to the hospitalisation and 
mortality of SLE patients, and need to be distinguished from 
Table 2. Immunosuppressants used in SLE
Indication Dose/route Important adverse effects Monitoring
AM (CQ) • SLE
• Lupus­like syndromes
4 mg/kg/day ideal body weight 
(or by height in number of 
200 mg tablets/week:
<154 cm, 4/week; 
154 ­ 174 cm, 5/week; 
>174 cm, 6/week)
• Skin hyperpigmentation
• Maculopathy
Screen for maculopathy annually 
after 5 years of use or annually in 
elderly
CS Severe organ 
involvement
IV methylprednisolone or 
oral prednisone 0.5 ­ 1 mg/kg
Numerous comorbidities 
(Table 3)
Lowest dose possible, taper rapidly 
MTX Skin, joint 7.5 ­ 25 mg/week • BM toxicity
• Hepatotoxicity, teratogenic
FBC, AST
CYC • Nephritis
• NPSLE
• Vasculitis
•  Other severe organ 
involvement
IVI pulse 10 ­ 20 mg/kg monthly 
(less toxic than oral CYC)
Euro­lupus regimen 500 mg IVI 
• Teratogenic
• Premature ovarian failure
• BM toxicity, infection
• Malignancies 
• FBC before infusion
•  Co­prescribe with MESNA to 
  ↓ bladder toxicity
AZA • Haem
• Skin
•  Nephritis 
maintenance 
1 ­ 5 mg/kg/day po • BM toxicity, infection
• Hepatotoxicity
? TPMT test before initiating, 
FBC in first 3 ­ 4 weeks of therapy, 
4­monthly FBC and AST
MMF • Haem
• Skin
•  Nephritis induction 
and maintenance 
2 g/day po in 2 divided doses • Teratogenic
•  GI disturbance (↓ dose and 
co­prescribe with H2­receptor 
antagonist)
• BM toxicity, infection
FBC, AST
CYA Haem 3 ­ 5 mg/kg/day po • Hypertension
• Renal dysfunction
• Impaired glucose tolerance
• Hirsutism
• Blood pressure monitoring
• Creatinine
 IVIG Haem (ITP/TTP) 2 g/kg for 5 consecutive days • Thrombosis
• Flu­like symproms
Rituximab Refractory nephritis, 
severe haematological 
disease and NPSLE 
(off­label uses)
500 ­ 1 000 mg/day 1 and 
day 15, IV 6­monthly or at 
relapse
• Serious infections:
•  Hepatitis B reactivation
•  Progressive multifocal leuko­
encephalopathy
 Hepatitis B serology prior to 
infusion
AM = antimalarial; CQ = chloroquine; CS = corticosteroids; MTX = methotrexate; CYC = cyclophosphamide; Haem = haematological SLE complications; AZA = azathioprine; 
MMF = mycophenylate mofetil; CYA = cyclosporin A; IVIG = intravenous immunoglobulins; NPSLE = neuropsychiatric lupus; IVI = intravenous infusion; BM = bone marrow; 
FBC = full blood count; AST = aspartate aminotransferase; MESNA = mercapto­ethanesulphonic acid; TPMT = thiopurine methyltransferase; ITP = immune thrombocytopenia; 
TTP = thrombotic thrombocytopenic purpura. 
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an SLE flare, bearing in mind that infections may also occur 
together with flares. Vaccination, vigilance, easy access to well­
informed clinicians and prompt antibiotic therapy are important 
measures. Moreover, SLE patients are at higher risk of pulmonary 
and extrapulmonary tuberculosis (TB); this risk is related to CS 
use, lymphopenia, and lupus disease itself.[8] Clinicians need to 
consider the possibility of TB in any ill SLE patient.
Atherosclerosis
Patients with SLE have a 2 ­ 5­fold increased risk of cardiac, 
cerebral or peripheral ar terial atherosclerosic events, and CV 
events are the leading cause of mortality in SLE.[9] Traditional 
Framingham CV risk factors do not fully explain the extent 
of the risk, as inflam matory and prothrombotic mechanisms 
underlie this premature atherosclerosis. Encouragingly, the 
CV risk may be reduced by regular exercise, statin therapy and 
possibly low­dose aspirin for any patient with ≥1 traditional 
risk factors for atherosclerotic disease, or with antiphospholipid 
antibodies.[10,11]
Antiphospholipid syndrome
Antiphospholipid antibodies are commonly encountered in 
SLE patients and are associated with a 50% risk of thrombo­
embolism.[12]  Despite the lack of evidence for primary prevention 
of thombosis and pregnancy loss, experts recommend low­
dose aspirin and AMs for SLE patients with anti phospholipid 
antibodies, especially when other risk factors for thrombosis 
coexist.[13] With regard to secondary prevention, patients with previous 
venous thrombosis, moderate­intensity warfarin therapy (target 
international normalised ratio (INR) 2.0 ­ 3.0) is appropriate. In the 
case of previous arterial thrombosis or stroke, high­intensity warfarin 
therapy (target INR 3.1 ­ 4.0) is preferable. Very recently it has been 
shown that non­vitamin K antagonist oral anticoagulants may 
be safe and effective alternatives to warfarin in antiphospholipid 
patients with previous venous events.[14] 
Management of major organ 
involvement
Nephritis
Nephritis is one of the most severe mani festations of SLE and one of 
the major predictors of poor prognosis. A urine dipstick test at each 
assessment is mandatory. An abnormal test warrants urine microscopy 
and a urine protein:creatinine ratio. Renal biopsy is indicated in any 
patient with active urinary sediment or significant proteinuria. 
Treatment of lupus nephritis consists of induction followed by a 
maintenance phase. Induction therapy for proliferative or membranous 
nephritis with CS combined with an immunosuppressive agent prevents 
progression to end­stage renal disease. CS may be given as pulse 
Table 3. Complications and comorbidities in SLE: Prevention and therapy
Comorbidity Comments Associations Prevention/therapy
Infections Bacterial and opportunistic 
respiratory and urinary tract 
infections
• CS dose
• Disease activity
•  Pneumococcal (5­yearly) and influenza 
vaccine (annually) 
• Vigilance by patient and healthcare team
• AM may be protective 
Tuberculosis Pulmonary and extrapulmonary • CS dose • INH prophylaxis if moderate dose (≥15 
mg/day) CS prescribed
Atherosclerotic CV disease Premature CV events • CS dose
•  Traditional and other risk 
factors (APLS, inflammation)
• Physical exercise
• Stop smoking 
• Low­dose aspirin 
• Statin and AM therapy
Hypertension • CS dose
• Nephritis
•  Target: <130/80 mmHg if nephritis is 
present) 
• ACEi or ARB if proteinuria
Dyslipidaemia • CS dose
• Nephrotic syndrome
•  Low threshold for intervention: SLE 
patients are a high­risk category
• Target LDL cholesterol <2.5 mmol/L
• Statins and AM 
Diabetes mellitus • CS dose
•  Obestity and other features of 
the metabolic syndrome
• AM may be protective
• Oral hypoglycaemic or insulin therapy
Osteoporosis • CS dose •  Calcium and vitamin D supplement to any 
patient receiving CS 
•  DEXA scan 5­yearly in postmenopausal 
women
• Bisphosphonate therapy if osteoporosis
Avascular bone necrosis Suspect if hip or knee pain, MRI 
to detect early
• CS dose
• APL antibodies
•  Bisphosphonates or core decompression if early
• Joint replacement if late
Uterine cervix carcinoma • CYC • HPV vaccine
• Annual Pap smears
Lymphoma 3­fold increase in SLE • Thorough clinical examination
CV = cardiovascular; MRI = magnetic resonance imaging; CS = corticosteroid; APLS = antiphospholipid antibody syndrome; AM = antimalarial; INH = isoniazid; 
ACEi = angiotensin­converting enzyme inhibitor; ARB = angiotensin receptor blocker; DEXA = dual­energy X­ray absorptiometry; HPV = human papillomavirus.
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methylprednisolone, or as oral CS, tapered over a few weeks to the lowest 
effective oral dose.[15] There is a high rate of relapse in patients treated 
with CS alone.[16] The current first­line choice of immunosuppressant is 
either CYC or MMF. High­dose, intermittent CYC (‘the NIH regimen’) 
or lower dose CYC (the Euro­Lupus regimen) are acceptable approaches, 
but in patients with severe disease (nephrotic­range proteinuria or renal 
impairment), and in black or mixed­ancestry patients, the high­dose 
CYC regimen may be preferable.[17] In young females who have not 
yet completed their families, MMF may be more suitable than CYC. 
Rituximab or tacrolimus may be useful in cases refractory or intolerant 
to conven tional therapies.[18,19] Importantly, early response to therapy 
predicts long­term renal outcome; therefore, patients with ongoing 
proteinuria and active urinary sediment at 6 months should be switched 
to another regimen.[20] Maintenance therapy should be with AZA or 
MMF for at least 3 years. Relapses are common, and diligent follow­up 
is important.
Neuropsychiatric lupus 
Neuropsychiatric lupus (NPSLE) is another of the serious 
manifestations of SLE, and may be secondary to sepsis, metabolic 
abnormalities, and drug side­effects, or may be directly related 
to the SLE (primary NPSLE). Nineteen NPSLE syndromes have 
been recognised, including seizures, psychosis, stroke, mood 
disorder, transverse myelitis, cognitive dysfunction, and peripheral 
neuropathy. The pathogenesis of primary NPSLE is thought to be 
either (i) immune­mediated inflammation or demyelination, and/
or (ii) ischaemic injury due to microangiopathy, thrombosis or 
emboli, frequently associated with antiphospholipid antibodies. 
Magnetic resonance imaging (MRI) is usually considered to be 
the gold standard imaging modality in the evaluation of cerebral 
lesions in patients with SLE, and a recent study showed that 
diffuse cortical MRI lesions are likely to be associated with 
immune­mediated inflammation, whereas focal white or grey 
matter hyperintensities are more likely to be ischaemic or related 
to vasculitis.[21] Inflammatory syndromes are best managed with 
immunosuppressive therapy, whereas ischaemic events may require 
anticoagulation.
Moreover, SLE is a well­known risk factor for depres sion, anxiety 
and fatigue, which tend to be poorly addressed by physicians. Several 
studies highlight the impor tance of focusing on and addressing 
individual patient’s psychosocial situations.
Heart
Myocarditis (best detected by MRI) and endocarditis are uncommon 
but serious complications of SLE, while pericarditis may lead 
to tamponade and is treated with moderate­dose CS and AMs. 
Refractory disease may respond to AZA, MMF, MTX, belimumab 
or rituximab. 
Cytopenias
Anaemia is common in SLE, and may be due to anaemia of chronic 
disease, iron deficiency, chronic renal insufficiency or autoimmune 
haemolytic anaemia (AIHA). AIHA must be treated with oral CS or 
pulse methylprednisolone, and if refractory may require AZA, CYC, 
MMF or splenectomy.
Immune thrombocytopenia is an independent risk factor for 
increased mortality in SLE and should be treated with oral CS or 
pulse methylprednisolone and AMs. In refractory cases, AZA, 
cyclosporin, intravenous immunoglobulins (IVIGs), MMF, danazol, 
CYC or splenectomy may be considered.
Thrombotic thrombocytopenic purpura is a rare but life­
threatening complication of SLE, characterised by severe thrombo­
cytopenia, microangiopathic haemolytic anaemia, neurological 
abnormalities, renal insufficiency and fever with fragmented red 
blood cells on peripheral blood smear. Plasmapheresis is the mainstay 
of treatment. Other therapies that have been used include high­dose 
CS, CYC, IVIGs and rituximab.
Skin
Acute and chronic skin lesions are very common, affecting 70 ­ 85% 
of patients, and are frequently of great concern to patients. Prompt 
therapy is necessary to avoid irreversible scarring, alopecia and 
depigmentation. All SLE patients should wear daily sunscreen 
(SPF ≥50). Treatment with AMs and topical CS is very effective. 
Small studies support the use of MTX, AZA, MMF, retinoids and 
dapsone for refractory cases.[22] 
Arthritis
Arthritis is a common presenting feature of SLE, and may be 
under­recognised. A recent MRI study showed a high incidence of 
subclinical hand and wrist arthritis, with erosions not infrequently 
seen, which may offer an explanation for the high prevalence of 
arthralgias in SLE patients.[23] Arthritis in SLE should be treated 
with AMs, short­term non­steroidal anti­inflammatory drugs, and 
low­dose (<10  mg) CS. Patients with ongoing arthritis may benefit 
from MTX.
Pregnancy
Because SLE is frequently a disease affecting women of 
childbearing age, fertility and pregnancy may be important 
issues. Patients should be reassured that successful full­term 
pregnancies are possible, and that the best time to conceive is once 
SLE is inactive. Pregnancy, particularly if it occurs in a patient 
with active SLE, may cause flares, especially worsening of lupus 
nephritis. CYC may affect fertility, and the risks are greatest if 
high cumulative doses are used (>15 g) and when given to women 
>30 years of age. Antiphospholipid antibodies are a risk factor 
for miscarriage, stillbirth, pre­eclampsia and premature delivery. 
Fetal congenital heart block is associated with anti­Ro/SSA or 
anti­La/SSB antibodies.
In pregnant SLE patients, AMs prevent flares and reduce the 
occurrence of congenital heart block. The incidence of fetal 
abnormalities is very low (although most studies have evaluated 
HQ, which may be safer than CQ). Hence, most experts believe 
that, after a detailed conversation with each patient, AMs should be 
continued during pregnancy and lactation. Glucocorticoids, AZA, 
and low­dose aspirin are considered safe in pregnancy, whereas 
MMF, CYC and MTX are contraindicated. Low­molecular­weight 
heparin with aspirin is indicated in patients with antiphospholipid 
antibodies and previous miscarriage to reduce the risk of pregnancy 
loss.[24] 
Contraception and hormone replacement therapy
Because of concerns of flares precipitated by exogenous oestrogens, 
women with SLE have traditionally been counselled against the 
use of hormonal oral contraceptives (OCs). Recent randomised 
controlled trials, however, have confirmed the safety of OCs in 
SLE.[25] Because of the risk of thrombosis (both venous thrombosis 
with thrombo­embolism and myocardial infarction), OCs should 
be avoided in patients with antiphospholipid antibodies. Long­
term hormone replacement therapy, although seemingly desirable 
in patients with premature menopause or osteoporosis, should 
be avoided because of the risk of mild to moderate flares and 
thrombosis.
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Newer therapies 
Improved understanding of the pathogenesis of SLE has paved the way 
for the development of new biologic agents. Rituximab, a humanised 
monoclo nal antibody targeting CD­20 recep tors on B lymphocytes, 
is useful in refractory nephritis, severe haematological disease 
and NPSLE. Belimumab inhibits B­lymphocyte stimulator and has 
recently been approved in the USA for mild to moderate disease. 
Several novel agents are currently being evaluated for safety and 
efficacy in lupus.
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Patient information websites 
Arthritis Foundation: http://www.arthritis.org.za/
Winelands SLE Support Group: http://wrc­lupus­support.co.za/
Two useful US lupus websites with particularly good information: 
https://www.hss.edu/lupus­programs.asp 
http://www.lupusny.org 
A lupus social media site: http://www.mylupusteam.com
